AbbVie Inc. (ABBV)
3 High-Yield Dividend Stocks to Buy in 2025
High-yield dividend stocks may not appeal to some investors. However, if you're among those investors looking for income, stocks that pay dividends regularly can be great additions to your portfolio.
11 Upcoming Dividend Increases, Including A Dividend King
Hormel Foods extends its 52-year dividend streak with a 2.6% increase; the group averages a 5.9% increase, median 5.8%. My strategy focuses on buying, holding, and adding to companies with consistent dividend growth and outperforming benchmarks. I use data from the "U.S. Dividend Champions" spreadsheet and NASDAQ to identify companies with at least five years of dividend growth.
3 Incredible Dividend Stocks to Buy in 2025
There might not be a better place to find winning stocks that can slowly make you wealthy over decades than the healthcare industry. It's an evergreen, multitrillion-dollar market that promotes growth and innovation because better healthcare saves lives.
AbbVie Takes $3.5B Impairment Charge for Failed Schizophrenia Drug
AbbVie (ABBV) shares fell Friday after the biotech firm announced it would take an estimated $3.5 billion impairment charge because of the failure of one of its drugs.
MoneyShow's Best Investment Ideas For 2025: Part 2
MoneyShow presents top investment ideas for 2025 from their contributors. This year's edition presents a broad mix of theme-based stock picks, momentum-driven high-flyers and beaten-up stocks with turnaround potential, along with some speculative plays and ETFs. Part 2 of this series includes Neo Performance Metals, Fannie Mae, Agnico Eagle, AbbVie, Morgan Stanley and Nomura Holdings, among others.
Abbvie to record $3.5 bln charge related to schizophrenia drug
Abbvie said on Friday it will record a charge of about $3.5 billion related to its experimental schizophrenia drug, emraclidine, which recently failed in two mid-stage studies.
Will AbbVie (ABBV) Beat Estimates Again in Its Next Earnings Report?
AbbVie (ABBV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
AbbVie Cuts 2024 EPS Guidance to Include Acquisition Costs
ABBV lowers adjusted earnings guidance for 2024 from $10.90-$10.94 per share to $10.02-$10.06 after incurring $1.6 billion in acquisition expenses in Q4.
AbbVie cuts 2024 profit forecast on acquisition expenses
AbbVie lowered its 2024 adjusted profit forecast on Monday as the drugmaker incurred $1.6 billion in acquisition expenses related to milestone payments as well as research-and-development costs.
The Smartest Dividend Stocks to Buy With $500 Right Now
Want to make a lot of money in the stock market without lots of stress? Buy and hold well-established companies that pay and increase dividends year after year.
2 No-Brainer Dividend Stocks to Buy With $250 in 2025
When it comes to dividend investing, there are two basic paths you can take. You could seek out businesses that are raising their payouts at a rapid pace, but these stocks tend to offer low yields.
